Vessl Therapeutics
Innovative vascular grafts enhancing hemodialysis outcomes and reducing complications for ESRD patients
About Vessl Therapeutics
Vessl Therapy focuses on developing advanced vascular grafts to improve the quality of life for patients with end-stage renal disease (ESRD) who rely on hemodialysis. Serving a critical need in the healthcare market, Vessl Therapy targets patients who undergo mechanical blood cleaning several times a week due to the unavailability of donor kidneys. The company operates in the medical technology sector, leveraging its proprietary platform to create grafts that enhance compatibility and reduce complications, thereby minimizing the need for frequent interventions and hospitalizations. Vessl Therapy's business model revolves around the research, development, and commercialization of these grafts, generating revenue through product sales to healthcare providers and institutions. The company aims to address the growing number of ESRD patients, driven by increasing prevalence of diabetes and hypertension, by offering a solution that extends the lifespan of synthetic grafts and reduces failure rates.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Apr 2021 | $16M | $64M | RunYoung Capital | — |
| LATE VC✓Equity / VC | Jan 2012 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Vessl Therapeutics is 370 monthly website visits, down 15.9% over the last three months. Vessl Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vessl Therapeutics in the Yokneam Ilit ecosystem
The Vessl Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
RunYoung Capital
Other known investors2 additional known investors
Technion Israel Institute of Technology- XHXT Hi-Tech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vessl Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vessl Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









